Cohen & Steers Global Realty Majors ETF (GRI)
- GlobeNewswire
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance G
- GlobeNewswire
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of Investigational New Drug (IND) enabling studies in systemic lupus erythematosus (SLE) program for GRI-0803 with IND filing expected in H2 2024 LA JOLLA, CA, May 13, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an i
- GlobeNewswire
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia. Details of the presentations are as follows: Oral Pr
